
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is well-positioned with a differentiated benefits management solution and strong client relationships, as indicated by high client retention rates and solid active working relationships. Management is confident in the company's future growth potential, with a focus on both greenfield and brownfield opportunities. With a strong balance sheet, disciplined cost management, and continued investment in new products and solutions, Progyny has potential for growth and value creation for shareholders.
Bears say
Progyny is facing increased competition in the fertility benefits market, with more RFPs being sent by clients currently working with competitors, potentially due to dissatisfaction with the company's value, returns, reporting, and cost management. There may also be a decrease in Progyny Rx revenue per ART cycle, which could impact revenue. Management may not be able to accurately predict the potential cost of breaking out Rx revenues, causing volatility in financials. Additionally, there are downside risks such as elevated attrition levels, utilization pressures, and economic downturns that could negatively impact the company's growth potential and revenue estimates.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares